Physician profile
Kimberly Lanier
NPI 1144558404
$666.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.31 · 2022: $93.72 · 2023: $15.30 · 2024: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.87 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.02 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $61.78 | 2024 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $46.58 | 2024 | Uzedy |
| Tris Pharma INC | $46.06 | 2024 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $45.62 | 2022-2024 | Rexulti, Abilify Maintena |
| Noven Therapeutics, LLC | $35.45 | 2024 | Xelstrym |
| Axsome Therapeutics, INC. | $33.10 | 2024 | Auvelity |
| Lundbeck LLC | $29.60 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $28.65 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $26.78 | 2022 | |
| Bausch Health US, LLC | $19.03 | 2021 | |
| Alkermes, INC. | $12.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Lanier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.